MannKind Corp.
MannKind Corp. focuses on the development and commercialization of inhaled therapeutic products for diabetic and other respiratory diseases.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying MannKind's stock with a target price of $8.4, indicating growth potential.
Financial Health
MannKind Corp. is generating solid revenue and profits, supported by strong cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring MNKD
Pharma M&A Targets (Metabolic Disease Biotechs)
Novo Nordisk's $5.2 billion acquisition of Akero Therapeutics highlights a strategic push into the MASH treatment market. This deal could trigger a wave of similar acquisitions, boosting the value of other biotech firms with promising drugs for metabolic diseases.
Published: October 10, 2025
Explore BasketAt-Home Treatment Revolution | FDA Approval Impact
The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug signals a major shift in chronic disease management. This creates an investment opportunity in companies that develop advanced drug delivery systems and support at-home patient care.
Published: September 1, 2025
Explore BasketPharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Published: August 19, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Afrezza revenue potential
Afrezza is the main commercial asset and could drive growth if uptake or label expansion improves, although sales trends have been uneven and outcomes are uncertain.
Inhaled delivery focus
Proprietary inhalation technology differentiates the company and may enable licensing opportunities, but technical, regulatory and commercial hurdles remain.
Partnerships & markets
Collaborations and market access are important for scaling reach; changes in reimbursement or competitive diabetes therapies can materially affect prospects.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
